AI-DRIVEN REAL-TIME MONITORING AND PREDICTIVE ANALYTICS SYSTEM FOR ENGINEERED T CELL THERAPIES IN CANCER MANAGEMENT

Abstract

The present invention relates to a specialized AI-driven data analytics platform tailored for optimizing engineered T cell therapies in patients, particularly those undergoing treatment for cancer, autoimmune diseases, and inflammatory conditions. Unlike general-purpose AI systems, this platform integrates advanced machine learning, deep learning, and fuzzy logic algorithms to continuously analyze and prioritize real-time data from multiple sources, including patient monitoring systems, laboratory tests, imaging modalities, wearable devices, and genomic profiles. The platform is specifically designed to predict and manage adverse events unique to T cell therapies, such as Cytokine Release Syndrome (CRS) and Tumor Lysis Syndrome (TLS), offering clinicians real-time, personalized guidance that dynamically adjusts treatment protocols during and after T cell infusion. The system's adaptive learning capabilities allow it to evolve by incorporating clinical feedback and patient outcomes, continuously refining its predictive models to enhance precision and effectiveness. By providing robust support for managing complex side effects and delivering actionable recommendations, this invention marks a significant advancement in the application of AI to oncology, offering a highly specialized, innovative approach to enhancing the safety and efficacy of engineered T cell therapies.

CPC Classifications